drugset / Trial / NCT01794897
Valacyclovir Augmentation for Cognitive and Functional Remediation in Schizophrenia
Phase 4
Completed
134 enrolled
University of Pittsburgh
Dr. Ram Manohar Lohia Hospital · collabStanley Medical Research Institute · collab
RandomizedParallel-groupTriple-blindBasic science
Summary
The effects of Valacyclovir (VAV) augmentation or placebo (PLA) as adjuncts to conventional antipsychotic drug treatment will be evaluated among patients with schizophrenia who have been exposed to herpes simplex virus type 1 (HSV-1). Hypothesis: Valacyclovir (VAV) augmentation improves (a) cognitive and (b) overall function among Herpes Simples Virus 1 (HSV-1) exposed early course schizophrenia patients.
Timeline
- Start
- 2013-02
- Primary completion
- 2016-09
- Completion
- 2016-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Valacyclovir | Unknown | 1.5 g | Oral |